April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Thioredoxin Interacting Protein Is a Novel Mediator of Retinal Inflammation and Neurotoxicity
Author Affiliations & Notes
  • Suraporn Matragoon
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia
  • Mohammed M. Al-Gayyar
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia
  • Mohammed A. Abdelsaid
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia
  • Bindu A. Pillai
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia
  • Azza B. El-Remessy
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia
  • Footnotes
    Commercial Relationships  Suraporn Matragoon, None; Mohammed M. Al-Gayyar, None; Mohammed A. Abdelsaid, None; Bindu A. Pillai, None; Azza B. El-Remessy, None
  • Footnotes
    Support  Career Development Award 2008-149 from JDRF (ABE) and a Grant from Vision Discovery Institute (VDI), Medical College of Georgia (ABE)
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1006. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Suraporn Matragoon, Mohammed M. Al-Gayyar, Mohammed A. Abdelsaid, Bindu A. Pillai, Azza B. El-Remessy; Thioredoxin Interacting Protein Is a Novel Mediator of Retinal Inflammation and Neurotoxicity. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1006. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Upregulation of thioredoxin interacting protein (TXNIP), an endogenous inhibitor of thioredoxin, can compromise major cellular antioxidant and antiapoptotic defense as well as stimulate proinflammatory cytokines expression suggesting a potential role of TXNIP in mediating cell death. The aim of this study is to examine the casual role of TXNIP expression in mediating retinal neurotoxicity and to screen the neuroprotective actions of verapamil, a calcium channel blocker and an inhibitor of TXNIP expression.

Methods: : Neurotoxicity was induced by intravitreal injection of N-methyl-D-aspartate (NMDA) in Sprague-Dawley rats, which received verapamil (10 mg Kg-1, po) or vehicle. Retinal neurotoxicity was examined by TUNEL assay and ganglion cell count. Expression of TXNIP, ASK-1, NFΚB, p38MAPK, JNK, cleaved PARP, caspase-3, nitrotyrosine and 4-HNE were examined by Western and slot-blot analysis. Release of TNF-α and IL-1β was examined by ELISA.

Results: : NMDA injection significantly enhanced TXNIP expression, decreased Trx activity resulting in significant increases in oxidative stress, glial activation and release of TNF-α and IL-1β. The enhanced TXNIP expression disrupted Trx/ASK-1 inhibitory complex leading to release of the ASK-1 and activation of the proapoptotic p38MAPK/JNK pathway as indicated by cleaved PARP and caspase-3 expression. Treatment with verapamil blocked these effects.

Conclusions: : Elevated TXNIP expression can contribute to retinal neurotoxicity by three different mechanisms; inducing release of inflammatory mediators as TNF-α and IL-1β, altering antioxidant status and disrupting Trx-ASK-1 inhibitory complex leading to activation of p38MAPK/JNK apoptotic pathway. Targeting TXNIP expression is a potential therapeutic target for retinal neurodegenerative disease.

Keywords: neuroprotection • oxidation/oxidative or free radical damage • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×